Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases

Aurinia Pharmaceuticals Inc. (AUPH)
Published on :

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline.

The Life Sciences Expansion Capitol: How Montgomery County, MD, Became a Top Life Sciences Destination

Aurinia Pharmaceuticals Inc. (AUPH)
Published on :

Last month, I was chosen to speak on a panel with leaders in the biotech industry and we all had two things in common: a great appreciation for this emerging life sciences region along with office headquarters in Montgomery County, MD.

Rockville’s Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

Aurinia Pharmaceuticals Inc. (AUPH)
Published on :

VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commitment to increasing access to equitable healthcare for individuals living with the autoimmune disease systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of grants to establish community-focused patient navigator programs. LN is one of the most serious and common complications of SLE and affects significantly more Black, Asian, and Hispanic individuals living with SLE than non-Hispanic white individuals with the condition. If left untreated, LN can cause irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.

Aurinia Wins FDA Approval for First LN Oral Drug

Aurinia Pharmaceuticals Inc. (AUPH)
Published on :

The FDA greenlit Aurinia’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen for LN, a serious progression of systemic lupus erythematosus (SLE), a chronic, complex and autoimmune disease. The approval not only marks the first medication in the United States specifically approved for active LN, it also marks the first for Aurinia, which is headquartered in Canada and last year opened its 30,000 square-foot commercialization facility in the BioHealth Capital Region.

5 Questions With… 2020 Recap

5 Questions With 2020
Published on :

In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.

2020’s Top 10 Most Read News Stories from the BioHealth Capital Region

Published on :

2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.

5 Questions with Cara Felish, VP, Commercial Operations, Aurinia Pharmaceuticals

Published on :

Sara Nayeem, M.D. is a Partner at New Enterprise Associates (NEA), a large diversified venture capital firm. Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Centrexion, Complexa, Cydan, Imara (IMRA), Tiburio, and a stealth targeted oncology company.